Artiva Biotherapeutics, Inc. - Common Stock (NQ:ARTV)

7.040 -0.010 (-0.14%)

Streaming Delayed Price Updated: 12:15 PM EDT, Sep 29, 2026 Add to My Watchlist

Price and Volume

Volume	146,401
Open	7.060
Bid (Size)	6.990 (100)
Ask (Size)	7.040 (400)
Prev. Close	7.050
Today's Range	6.920 - 7.180
52wk Range	2.710 - 14.53
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease

September 23, 2026

Oral presentation to highlight updated clinical data from 11 patients with Sjögren disease (SjD) treated with AlloNK and rituximab, with six months or more of follow-up

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

September 17, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+66.4%	+66.4%
1 Month	-37.7%	-37.7%
3 Month	-26.5%	-26.5%
6 Month	+29.2%	+29.2%
1 Year	+141.1%	+141.1%

More News

Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026

September 08, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September

September 02, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 06, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

June 23, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

June 08, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

May 28, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases

May 19, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development

May 19, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

May 14, 2026

Via FinancialNewsMedia

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

May 08, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 08, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

May 08, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

March 10, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

February 25, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

February 24, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

February 19, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability

January 21, 2026

From Artiva Biotherapeutics, Inc.

Via GlobeNewswire

Keep an eye on the top gainers and losers in Tuesday's session. ↗

December 16, 2025

Via Chartmill

These stocks are moving in today's session ↗

December 16, 2025

Via Chartmill

Which stocks are moving on Monday? ↗

December 15, 2025

Via Chartmill

Myseum (NASDAQ: MYSE) Realizes $6.8M in Asset Sale – Watch AMCI, ARTV, QIPT, SURG Today!

December 15, 2025

Via AB Newswire

Monday's session: top gainers and losers ↗

December 15, 2025

Via Chartmill

Frequently Asked Questions

Is Artiva Biotherapeutics, Inc. - Common Stock publicly traded?

Yes, Artiva Biotherapeutics, Inc. - Common Stock is publicly traded.

What exchange does Artiva Biotherapeutics, Inc. - Common Stock trade on?

Artiva Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Artiva Biotherapeutics, Inc. - Common Stock?

The ticker symbol for Artiva Biotherapeutics, Inc. - Common Stock is ARTV on the Nasdaq Stock Market

What is the current price of Artiva Biotherapeutics, Inc. - Common Stock?

The current price of Artiva Biotherapeutics, Inc. - Common Stock is 7.040

When was Artiva Biotherapeutics, Inc. - Common Stock last traded?

The last trade of Artiva Biotherapeutics, Inc. - Common Stock was at 09/29/26 12:15 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.